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Cerebral autosomal-dominant arteriopathy with subcor-tical infarcts and leukoencephalopathy (CADASIL) is 
a monogenic form of cerebral small vessel disease (SVD) 
caused by mutations in the Notch3 gene, and it is associated 
with recurrent lacunar strokes and cognitive decline leading 
to dementia.1
Even before the onset of stroke and dementia, cognitive 
deficits are detected in patients with CADASIL,2 particularly 
in areas of attention, processing speed, and executive func-
tions.2–5 Many studies have shown a similar pattern to older 
patients with sporadic SVD,6 although some studies have also 
shown early deficits in memory retrieval.3
Cognitive screening provides clinicians with important infor-
mation about disease progression and cognitive disability as well 
as providing rapid measures for use in clinical trials. However, 
there are few targeted screening measures for SVD in general 
or, in particular, for patients with CADASIL where deficits may 
be subtle. Measures developed for cortical dementias such as 
the Mini-Mental State Examination7 and Alzheimer's Disease 
Assessment Scale- Cognitive Subscale test8 are relatively insen-
sitive to subtle changes in key areas of function in SVD, namely 
executive function and information processing speed because 
of their lack of adequate measurement of these processes.6,9 An 
alternative is the Brief Memory and Executive Test (BMET), 
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an open access brief screening tool specifically designed for the 
detection of cognitive deficits in SVD,10,11 which has been exten-
sively validated in patients with sporadic SVD. The Montreal 
Cognitive Assessment (MoCA) may also be a sensitive measure, 
and it has been validated in a general stroke population12 and been 
shown to be associated with subcortical white matter disease.13
The primary aim of our study was to assess the use of the 
BMET and the MoCA as a rapid screening tool for the detec-
tion of vascular cognitive impairment (VCI) and cognitive dis-
ability in CADASIL. The study also examines important risk 
factors and background variables in relation to VCI.
Methods
Participants
Sixty-six patients (mean age=51.6, SD=9.5, range=34–70; sex: 
male=38%) with a genetically confirmed diagnosis of CADASIL, 
based on a typical disease-causing cysteine altering mutation in the 
Notch3 gene, were recruited prospectively from 2 national CADASIL 
referral clinics at St. George’s Hospital, London, United Kingdom 
and Addenbrooke’s Hospital, Cambridge, United Kingdom. None of 
the patients had a clinical diagnosis of dementia. All had brain mag-
netic resonance imaging.
Five hundred and two healthy controls were recruited from family 
doctor practices or other volunteer groups in South London as part 
of the previous BMET validation study.11 Individuals with a history 
of stroke, transient ischaemic attack, major central neurological or 
major psychiatric disease were excluded. An age- and sex-matched 
control population (n=66) were randomly selected from this larger 
sample. Random sampling was conducted in R (105 iterations) with 
the probability of being selected weighted for sex. Controls older 
than 70 (n=167) years were removed. There were 9 resultant samples 
closely matching the CADASIL group for the age and sex ratio. A 
random number generator then selected sample No. 6 from these 
(age=mean=51.6, D=9.0, range=36–70; sex=male=36%). Full details 
of participant demographics are presented in Table 1.
Ethics
Participants were recruited as part of studies approved by United 
Kingdom National Health Service ethics committees. All participants 
gave informed consent.
Cognitive Screening Measures
The BMET is a fully normed screening test developed for the detec-
tion of VCI.10,11 It takes around 10 minutes to administer and con-
tains 4 items sensitive to executive dysfunction/processing speed: (1) 
letter-number matching, (2) motor-sequencing, (3) letter-sequencing, 
and (4) number-letter sequencing; and 4 items sensitive to memory 
impairment: (1) orientation, (2) 5-item repetition, (3) 5-item recall, 
and (4) 5-item recognition. Raw scores are converted into age-scaled 
scores of 0, 1, or 2. The total BMET score is out of 16 with a cutoff 
of ≤13 having previously been shown to indicate impairment.11 For 
participants aged 34 to 39 years, aged 40 test norms were applied. 
Table 1. Participant Demographics and Neuropsychology Scores
 CADASIL (n=66) Controls (n=66) Comparison
Age (mean, SD, range) 51.5, 9.4, 34–70 51.6, 9.0, 36–70 t(130)=−0.04, P=0.970
Sex (% male) 37.9% 36.4% X2(1)=0.03, P=0.857
Ethnicity (% white, black, Asian, other) 92.5%, 1.5%, 4.5%, 1.5% 90.9%, 3%, 0%, 6.1% X2(3)=5.1, P=0.162
NART FSIQ (mean, SD), n=56, 65 111.5, 8.5 119, 5.8 t(95.52*)=−5.62, P<0.0001
Clinical stroke, % 54.5 0 n/a
White matter disease severity (Fazekas 
scale,† % ≥2), n=58
95% n/a n/a
Treated hypertension, % 33.3% 18.2% X2(1)=3.94, P=0.047
Treated hypercholesterolaemia, % 57.6% 10.6% X2(1)=32.40, P<0.0001
Diabetes mellitus, % 3% 1.9% X2(1)=0.14, P=0.704
Smoking, %
  Never 50.0 60.6 X2(2)=0.98, P=0.612
  Ex 34.8 28.8  
  Current 10.6 10.6  
  Not available 4.5 0  
BMET total score (mean, SD) 12.4, 3.9 15.3, 1.2 t(76.78*)=−5.76, P<0.0001
BMET executive/PS subscale (mean, SD) 6.5, 2 7.8, 0.5 t(73.47*)=−5.18, P<0.0001
BMET orient/mem subscale (mean, SD) 5.9, 2.2 7.5, 0.9 t(85.66*)=−5.34, P<0.0001
MoCA total score (mean, SD) n=30, 54 23.7, 5.5 27.4, 2 t(33.45*)=−3.59, P<0.0001
IADL (% impaired) 21% 0% X2(1)=18.40, P<0.0001
BADL (% impaired) 27% 2% X2(1)=17.77, P<0.0001
BADL indicates Barthel Activities of Daily Living; BMET, Brief Memory and Executive Test; IADL, instrumental activities of daily living; 
MoCA, Montreal Cognitive Assessment; NART_FSIQ, National Adult Reading Test Full-Scale Intelligence Quotient; PS, processing speed; and 
orient/mem, orientation/memory subscale.
*df adjusted for Levene test for equality of variances.
†Adjusted Fazekas scale for white matter lesions 0 absent to 3 confluent.
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Recent normative data for BMET can be found at http://www.bmet.
info. Background interviews and testing were performed in 1 hour 
research windows to allow maximum participation of patients who 
were not local to the clinic location in which they were recruited and 
tested, also reflecting neurological clinic involvement. Where time 
was available, participants also competed other background measures 
and the MoCA (n=84).14 The MoCA contains 8 sections developed 
to be relevant to mild cognitive impairment and validated in stroke: 
(1) visuospatial/executive, (2) naming, (3) memory, (4) attention, (5) 
language, (6) abstraction, (7) delayed recall, and (8) orientation. The 
MoCA has a clinical cutoff of <26.
Additional Measures
The National Adult Reading test (NART-R),15 a measure of oral read-
ing vocabulary and premorbid intelligence quotient (IQ; n=121); 
The Barthel Activities of Daily Living (BADL) scale,16 a measure 
of general disability; and the instrumental activities of daily living 
(IADL),17 a measure of cognitive disability (n=127).
Statistical Analysis
Demographic variables and cognitive test total scores were compared 
using t tests and χ2 tests. To consider the impact of risk factors and 
background demographics on VCI status in CADASIL, we calculated 
Pearson χ2 for categorical variables and Wald χ2 for continuous variables. 
This was completed for both the MoCA and BMET diagnoses of VCI.
The sensitivity and specificity of the BMET and the MoCA clinical 
cutoffs for VCI detection was analyzed using receiver operating charac-
teristic (ROC) curves. VCI status was determined using our predefined 
criteria: modified Petersen mild cognitive impairment threshold of a 
score of ≤−1.5 SD from the control mean18 on ≥4 BMET subtests.10,11 
To ensure that we did not inflate the effect of the BMET in predicting 
VCI, we included a second more stringent definition of VCI, which 
combined both the modified Petersen criteria and the MoCA clini-
cal cutoff for cognitive impairment (<26). To allow for a comparison 
of the MoCA and BMET, the BMET ROC analysis was rerun in the 
same population of patients who also had MoCA scores. To further 
establish predictive validity of the tests, ROC analyses were calculated 
for an important independent indicator of cognitive disability, impair-
ment of IADL. Reduced IADL was calculated as a score of ≤7 on the 
IADL, indicating a lack of independence on any of the domains of the 
IADL. To ensure any prediction of this outcome was not because of 
general disability, we examined the association with BADL total scores 
and also clinical impairment on the BADL as defined in the study by 
Hollocks et al,19 using linear and binary logistic regression.
Post-hoc analyses of disease markers and screening test total scores 
were carried out using linear regression analyses. Post-hoc analyses 
of the impact of premorbid IQ on screening test scores for detecting 
VCI were carried out using discriminant function analysis. All analy-
ses were carried out in SPSS (v21).
Results
Descriptive Data for Groups
The CADASIL group had significantly lower total scores than 
controls on the BMET (t(76.78)=−5.76, P<0.0001). This was 
also true for both the executive/processing speed subscale 
(t(73.47)=−5.18, P<0.0001) and the orientation/memory sub-
scale (t(85.66)=−5.34, P<0.0001). Using the clinical cutoff of 
≤13 on the BMET, the number of patients with CADASIL 
defined as having cognitive impairment was 32 of 66 com-
pared with 7 of 66 for the controls. For the participants who 
completed the MoCA, the CADASIL group had significantly 
lower scores than the controls t(33.45)=−3.59, P<0.0001). 
Using the MoCA clinical cutoff of <26, the number of patients 
with CADASIL defined as having cognitive impairment was 
17 of 30 compared with 19 of 54 controls.
Risk Factors and VCI
For VCI as diagnosed by the BMET, there were no signifi-
cant effects of hypertension (X2(1)=0.03, P=0.862), hyperlip-
idemia (X2(1)=0.62, P=0.432), diabetes mellitus (X2(1)=0.87, 
P=0.350), current smoking status (X2(1)=0.127, P=0.722), 
ethnicity (X2(3)=5.35, P=0.148), sex (X2(1)=0.20, P=0.655), 
age (X2(1)=0.005, P=0.946), or lesion load (X2(2)=1.57, 
P=0.455). However, there was a significant effect of previ-
ous stroke (X2(1)=7.52, P=0.006) and also premorbid IQ 
(X2(1)=9.41, P=0.002) on VCI.
For the MoCA diagnosis of VCI, there were no significant 
effects of any risk factors or background variables: hyper-
tension (X2(1)=0.34, P=0.558), hyperlipidemia (X2(1)=0.14, 
P=0.713), diabetes mellitus (X2(1)=0.64, P=0.424), current 
smoking status (X2(1)=0.006, P=0.936), ethnicity (X2(2)=3.53, 
P=0.171), sex (X2(1)=0.89, P=0.346), age (X2(1)=0.382 
P=0.537), lesion load (X2(2)=3.07, P=0.215), or history of 
stroke (X2(1)=0.362, P=0.547). Premorbid IQ approached sig-
nificance (X2(1)=2.90, P=0.089).
Markers of Disease and Cognitive Impairment
Post-hoc regression analyses were used to explore further 
the relationship between disease markers and cognitive 
impairment. These showed that a history of previous stroke 
was significantly associated with lower BMET total scores 
(β=−0.378, P=0.002), and this held when age was included in 
the model (β=−0.376, P=0.004). Fazekas score was not, how-
ever, associated with total BMET score (β=−0.091, P=0.496; 
with age included: β= 0.052, P=0.737). The same analyses 
were carried out for the MoCA. This showed no significant 
association between a history of previous stroke and MoCA 
total score (β=−0.279, P=0.135; with age included in the 
model: β=−0.240, P=0.186). Fazekas score was not signifi-
cantly associated with total MoCA score (β=−0.267, P=0.170; 
with age included in the model: β=−0.102, P=0.607).
Predicting VCI in CADASIL
On the basis of the modified Petersen criteria, as used in pre-
vious analyses,10,11 VCI status was given to 24 of 66 patients 
with CADASIL and 2 of 66 controls. ROC curves were calcu-
lated to examine the detection of VCI using the BMET total 
score. ROC analysis including all participants calculated an 
area under the curve of 0.94 (95% CI, 0.87–1). A classifica-
tion of cases based on a BMET cutoff of ≤13 indicated that 
this criterion had a sensitivity of 85% and specificity of 84% 
with a total predictive value (TPV) of 84%. This cutoff gave 
a good balance between sensitivity and specificity. Alternative 
cut-off points are presented in Table 2. When all controls were 
treated as unimpaired in the same analysis, a BMET cutoff of 
≤13 had a sensitivity of 88% and specificity of 85% with a 
TPV of 84%.
Eighty-four participants (30 CADASIL and 54 controls) 
had completed the MoCA. These data were used for a sec-
ondary analysis to examine the BMET and the MoCA’s pre-
diction of VCI in parallel. For this subgroup of participants, 
ROC analysis of the BMET calculated an area under the 
curve of 0.95 (95% CI, 0.91–1). A classification of VCI cases 
based on the BMET cutoff of ≤13 gave 81% sensitivity and 
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88% specificity, with a TPV of 87%. A ROC analysis of the 
MoCA calculated an area under the curve of 0.87 (95% CI, 
0.77–0.97). A classification of VCI cases based on the MoCA 
clinical criterion of a score of <26 gave 81% sensitivity and 
79% specificity, with a TPV of 81%. When all controls were 
treated as unimpaired using the same analysis, the BMET had 
a sensitivity of 80% and specificity of 87% with a TPV of 
86%, and the MoCA had a sensitivity of 80% and a specificity 
of 78% with a TPV of 79%.
To avoid bias, adjusted criteria for VCI were created where 
the participant was defined as impaired if meeting both the 
original BMET criteria for VCI and the MoCA clinical crite-
rion of <26. The ROC analysis for BMET calculated an area 
under the curve of 0.99 (95% CI, 0.99–1). A classification 
of VCI cases based on the BMET cutoff of ≤13 gave 100% 
sensitivity and 98% specificity, with a TPV of 99%. An ROC 
analysis of the MoCA calculated an area under the curve of 
0.81 (95% CI, 0.67–93). A classification of VCI cases based 
on the MoCA clinical criterion of a score <26 gave 80% sen-
sitivity and 83% specificity, with a TPV of 82%. When all 
controls were treated as unimpaired using the same analysis, 
the BMET had a sensitivity of 100% and specificity of 91% 
with a TPV of 93%, and the MoCA had a sensitivity of 87% 
and a specificity of 80% with a TPV of 81%. A summary of 
the predictive values are given in Table 3.
Premorbid IQ and VCI Prediction
Following the finding that premorbid IQ showed a relation-
ship with cognitive test outcomes, we examined whether 
the addition of premorbid IQ to the screening test cutoffs 
improved predictive accuracy for VCI. Using discriminant 
function analyses and adding in premorbid IQ to predict VCI 
(Petersen criteria), we found that for the whole group sensitiv-
ity increased to 91% compared with 85% using the BMET 
alone and specificity remained the same at 84%. When we 
took only those participants completing both screening tests, 
we found that for the BMET plus IQ, sensitivity increased to 
92% from 81% and specificity marginally increased to 89% 
from 88% compared with the BMET alone. Similarly, for the 
MoCA plus IQ, sensitivity increased to 92% from 81% and 
specificity increased to 84% from 79% compared with the 
MoCA alone.
Predicting Cognitive Disability: 
Impaired Activities of Daily Living
Using IADL as a marker for cognitive disability, we re-
examined the predictive validity of the BMET (n=127; 
CADASIL=61, controls=66) and the MoCA (n=79; 
CADASIL=25, controls=54). We found that 13 of 61 patients 
with CADASIL and 0 of 66 controls in the original sample 
had cognitive disability. Using ROC analysis to determine the 
BMETs classification of patients with and without cognitive 
disability gave an area under the curve of 0.89 (95% CI, 0.78–
1.0). The clinical cutoff of ≤13 predicted cognitive disability 
with a sensitivity of 92%, specificity of 77%, and a TPV of 
79%. For the MoCA, the area under the curve was 0.78 (95% 
CI, 0.53–1.0). The clinical cutoff of <26 predicted cognitive 
disability with a sensitivity of 75%, specificity of 76%, and 
TPV of 76%.
For a validity check, we calculated regression models to 
consider whether the BMET and MoCA’s relationship with 
the activities of daily living were specific to cognitive dis-
ability or a consequence of more general disability in patients 
with CADASIL. The IADL, an index of cognitive disability, 
and the BADL, an index of general disability, were included in 
the models. We found that the BMET significantly predicted 
IADL (F=9.05, df=1, P>0.0001) but not BADL total scores 
(F=0.99, df=1, P=0.325); and that the MoCA similarly pre-
dicted IADL (F=5.63, df=1, P=0.026) but not BADL total 
scores (F=0.814, df=1, P=0.376), suggesting specificity to 
cognitive disability. An additional analysis taking clinical 
impairment as the outcome variable showed the same pat-
tern of results for the BMET (IADL impairment: X2(1)=7.22, 
P=0.007; BADL impairment: X2(1)=0.495, P=0.483); the 
MoCA (IADL impairment: X2(1)=5.46, P=0.019; and the 
BADL impairment: X2(1)=0.053, P=0.818).
Discussion
Main Findings
On the basis of the modified Petersen criteria,10,11 cognitive 
impairment was found in 24 of 66 patients with CADASIL 
and 2 of 66 controls. Compared with age-matched controls, 
the CADASIL group showed a significant reduction in scores 
Table 2. Alternative Clinical Cutoffs for the Prediction of VCI 
Using the BMET





Possible cut-off points indicated from the ROC analysis. ≤13 is the existing 
clinical cutoff for the BMET test. BMET indicates Brief Memory and Executive 
Test; ROC, receiver operating characteristic; and VCI, vascular cognitive 
impairment.
Table 3. Summary of Predictive Values in for All Participants
Screening 





BMET ≤13 Modified Petersen criteria 85 84
BMET ≤13 Cognitive disability (IADL) 92 77
BMET ≤13* Modified Petersen criteria 
plus MoCA <26
100 98
MoCA <26* Modified Petersen criteria 
plus MoCA <26
80 83
MoCA <26* Cognitive disability (IADL) 75 76
Predictive values of the BMET and MoCA clinical cutoffs where different 
criteria for VCI are used. The predictive values are based on all participants 
(CADASIL and controls) included in analyses. BMET indicates Brief Memory 
and Executive Test; CADASIL, cerebral autosomal-dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy; IADL, instrumental activities of 
daily living; MoCA, Montreal Cognitive Assessment; and VCI, vascular cognitive 
impairment.
*Analysis performed only on the subgroup who had completed both the BMET 
and the MoCA (n=84).







2486  Stroke  October 2016
on both the BMET and the MoCA and a higher prevalence 
of VCI.
The primary aim of the study was to look at the use of the 
BMET and the MoCA, 2 rapid screening measures, in predict-
ing cognitive impairment in CADASIL. The BMET clinical 
cutoff was derived from normative data used as age-scaled 
markers by which to compare sporadic SVD cases.11 The 
MoCA clinical cutoff was taken from the test scoring crite-
ria outlined in the manual.14 ROC analyses revealed a high 
predictive value for the BMET clinical cutoff with a TPV 
comparable to that shown previously in sporadic SVD cases11 
(CADASIL cases: TPV=84% sporadic cases: TPV=78%). 
This was maintained across different diagnostic criteria for 
VCI. The MoCA also performed well. There was, however, 
a slightly poorer performance than the BMET when both 
tests were analyzed in parallel, possibly because of the less-
sensitive measures of executive function and the lack of pro-
cessing speed component in the MoCA. In a previous study11 
of patients with sporadic SVD, the BMET performed well 
and with similar sensitivity and specificity levels as the cur-
rent study. However, the MoCA performed less well show-
ing a particularly poor specificity. It may be that the current 
MoCA cutoff for cognitive impairment over predicts deficits 
in healthy older adults but be suitable for slightly younger age 
group, where more subtle deficits are indicative of reduced 
function. In conclusion, the BMET may have advantages over 
the MoCA for sporadic, older patients, but not necessarily 
for younger patients with CADASIL. It should be noted that 
BMET focuses specifically on executive functioning, process-
ing speed and memory, the reason being that sporadic SVD is 
particularly associated with executive dysfunction and lower 
processing speed. The MoCA may detect more widespread 
cognitive deficit, if it exists, including, for example, visuocon-
structional impairment.
In an analysis of the tests' predictive accuracy of cognitive 
disability, the BMET and MoCA were able to predict, with 
good accuracy, the existence of cognitive disability as mea-
sured by the IADL scale. The data indicated that a quarter 
of patients completing the IADL scale (13/61) had a deficit 
affecting their activities of daily living. A reduction in IADLs 
is strongly associated with reduced cognitive functioning, 
which leads to impairment in everyday activity.20 Of impor-
tance is that this study showed a clear and specific prediction 
of cognitive disability but not general disability. This confirms 
that these associations were not a consequence of overall dis-
ability. Functional disability is an important clinical outcome 
of CADASIL, and predicting this is important for assessing 
patient needs. Moreover, these findings were in individu-
als without diagnoses of dementia, highlighting the need for 
measures sensitive to the functional impairment seen in this 
patient group.
Secondary Analyses
Examining the subdomains of the BMET, significant deficits 
were seen in both executive functioning/processing speed 
and also memory. Although it is well established that many 
patients with CADASIL display deficits in executive func-
tions and processing speed before the onset of dementia,2,4 
memory deficits have been less commonly identified in previ-
ous studies.3 They may, however, be worthy of consideration 
in neuropsychological assessment of this population. Of note 
is that the distribution of magnetic resonance imaging white 
matter hyperintensities in CADASIL, although broadly simi-
lar to sporadic disease, has more prominent temporal lobe 
involvement.21
Consideration of background variables and risk factors 
showed that CADASIL patients with a previous stroke were 
more likely to have a diagnosis of VCI on the BMET than 
those without. Furthermore, previous stroke predicted overall 
BMET score even when age was accounted for in the analysis. 
This is in line with previous research showing executive dys-
function and reduced processing speed of a similar magnitude 
to sporadic SVD for CADASIL cases with a history of stroke,6 
and a recent study showed that incident dementia is associated 
with recurrent stroke in CADASIL.22 Fazekas score, however, 
did not show a significant association with cognitive outcomes 
on either scale. It is worth noting that this may be because of 
its relative insensitive to subtle changes in lesion extent, par-
ticularly in this population where 95% were graded as 2 or 3. 
This issue may be better explored in future studies using more 
quantitative measures of lesion load. Certainly, white matter 
disease has previously been shown to be associated with the 
MoCA when using diffusion tensor imaging to map micro-
structural damage.13 Furthermore, the strategic location of 
white matter damage has also been shown to be of importance 
when assessing the relationship between lesion and cognition 
in SVD.23 This information is not captured by Fazekas and 
therefore may add to its insensitivity. Future analyses may 
need to consider lesion locations in addition to extent.
Our secondary analyses also indicated a significant asso-
ciation between premorbid IQ and cognitive impairment on 
the BMET, with a borderline association with the MoCA. 
Premorbid IQ is thought to be associated with predisease neu-
ral organization, described as cognitive reserve.24 Although 
reserve in SVD is largely understudied, there is evidence that 
it might mitigate the relationship between white matter disease 
and cognitive impairment in normal aging25 and also in patients 
with CADASIL.26 Because of this potential influence on cogni-
tive outcomes, we performed a further analysis where premor-
bid IQ was added into the predictive model for the detection 
of VCI. Our results showed that even with already high levels 
of prediction by the BMET and MoCA, the predictive value 
was further enhanced by the inclusion of premorbid IQ. This 
emphasises the importance of considering core background 
variables when performing cognitive screening in patients with 
SVD and also suggests a potentially fruitful avenue for future 
research projects looking at cognitive reserve in SVD.
It is acknowledged that these findings need further con-
sideration in larger population. Furthermore, it is noted that 
the BMET is normed only from age 40 years, and that the 
use of these norms for those aged <40 (34–39) years may 
have reduced slightly the levels of impairment in the scores 
from this group. Furthermore, the lack of normative data for 
the MoCA may have also reduced its potential sensitivity. A 
future important direction for cognitive screening measures is 
their adaptability to younger population.
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In conclusion, the results of this study demonstrate that 
a high frequency of cognitive impairment in nondemented 
patients with CADASIL and show that the BMET and the 
MoCA provide a sensitive and specific tools for detecting cog-
nitive deficits in this population.
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